Alliance for Pandemic Preparedness

December 14, 2020

The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020

Category:

Topic:

Keywords (Tags):

On Dec 12, 2020, the Advisory Committee on Immunization Practices issued an interim recommendation for use of the Pfizer-BioNTech COVID-19 vaccine in persons in the US aged ≥16 years to prevent COVID-19. Vaccination consists of 2 doses administered intramuscularly 3 weeks apart. The recommendation was primarily informed by findings from a randomized, double-blind, placebo-controlled Phase II/III trial (n = 43,252, median age 52 years) reporting 95% efficacy in preventing symptomatic laboratory-confirmed COVID-19 among persons without previous SARS-CoV-2 infection during a median 2-months of follow-up.

Oliver et al. (Dec 13, 2020). The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020. MMWR. https://doi.org/10.15585/mmwr.mm6950e2